Bluejay initiates SYMON multicenter study of Symphony IL-6 test in sepsis patients

Bluejay Diagnostics, Inc.

Study will monitor IL-6 in sepsis/septic shock patients admitted to ICU; aims to predict 28-day mortality.
Study design incorporates feedback from pre-submission meetings with the FDA held earlier in 2023.
Symphony System delivers results from whole blood in ~20 minutes; study listed on clinicaltrials.gov (NCT06181604).
CEO Neil Dey says study moves company 'one step closer to commercialization' and may identify competitive advantages.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.